Wunderlicha C,Schmeisser A,Heerwagen C,et al.Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1knockout mice[J].Pulmonary Pharmacology&Therapeutics,2007,127:611-619.
[2]
Geraci MW,Moore M,Gesell T,et al.Gene expression patterns in the lungs of patients with primary pulmonary hypertension:agene microarray analysis[J].Circ Res,2001,88:555-562.
[3]
Jasmin JF,Mercier I,Dupuis J,et al.Short-term administration of a cell-permeable Caveolin-1peptide prevents the ventricular hypertrophy[J].Circulation,2006,114(9):912-920.
[4]
Razani B,Engelman JA,Wang XB,et al.Caveolin-1null mice are viable,but show evidence of hyperproliferative and vascular abnormalities[J].J Biol Chem,2009,276:38 121-38 138.
Yao J,Xiong M,Tang B,et al.Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1and-9expression in a carotid arteryjugular vein shunt pulmonary hypertension model in rats[J].Eur J Cardiothorac Surg,2012,42:e121-e127.
[7]
Pei Y,Ma P,Wang X,et al.Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism[J].Eur J Pharmacol,2011,666:165-172.